List of Excipients in Branded Drug POTASSIUM CHLORIDE EXTENDED-RELEASE

Generic Drugs Containing POTASSIUM CHLORIDE EXTENDED-RELEASE

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY LLC dba Vangard Labs	potassium chloride extended-release	0615-8399	CELLULOSE, MICROCRYSTALLINE
NCS HealthCare of KY LLC dba Vangard Labs	potassium chloride extended-release	0615-8399	CROSCARMELLOSE SODIUM
NCS HealthCare of KY LLC dba Vangard Labs	potassium chloride extended-release	0615-8399	ETHYLCELLULOSES
NCS HealthCare of KY LLC dba Vangard Labs	potassium chloride extended-release	0615-8399	HYDROXYPROPYL CELLULOSE
NCS HealthCare of KY LLC dba Vangard Labs	potassium chloride extended-release	0615-8399	TALC
Major Pharmaceuticals	potassium chloride extended-release	0904-7201	CELLULOSE, MICROCRYSTALLINE
Major Pharmaceuticals	potassium chloride extended-release	0904-7201	CROSCARMELLOSE SODIUM

What are the Most Frequently-Used Excipients in POTASSIUM CHLORIDE EXTENDED-RELEASE?

# Of NDCs	Excipient
35	CELLULOSE, MICROCRYSTALLINE
21	CROSCARMELLOSE SODIUM
14	CROSPOVIDONE
14	DIETHYL PHTHALATE
26	ETHYLCELLULOSE
9	ETHYLCELLULOSES
21	HYDROXYPROPYL CELLULOSE

Potassium Chloride Extended-Release: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 5, 2026

Potassium chloride extended-release is a mature, high-volume oral solid-dose market with limited active patent protection and substantial formulation complexity. The commercial opportunity is strongest in differentiated modified-release tablets, sprinkleable capsules, lower-irritation dosage forms, hospital and specialty packaging, and products that improve dose flexibility or administration for patients with dysphagia.

The active ingredient is inexpensive and widely available. Competitive advantage therefore depends on manufacturing reliability, gastrointestinal tolerability, dose uniformity, abuse-resistant packaging, supply continuity, and regulatory execution rather than API exclusivity.

What is the market for potassium chloride extended-release products?

Potassium chloride extended-release products replace potassium losses in patients with hypokalemia or conditions requiring chronic potassium supplementation. U.S. products are sold primarily as extended-release tablets, microencapsulated capsules, and liquid or powder alternatives.

Common U.S. product families include:

Product family	Typical dosage strengths	Dosage form	Commercial positioning
Klor-Con M	8, 10, 15, 20 mEq	Extended-release tablet	Matrix or coated tablet; major branded reference
Klor-Con	8, 10, 20 mEq	Extended-release tablet	Brand and generic competition
Micro-K	8 mEq	Extended-release microencapsulated capsule	Smaller particles and flexible administration
Generic potassium chloride ER	8, 10, 15, 20 mEq	Tablet or capsule	Price-led multisource market
Potassium chloride oral solution	Various concentrations	Liquid	Patients unable to swallow solid dosage forms

Potassium chloride extended-release products are not interchangeable solely because they contain the same number of milliequivalents. Release rate, dosage form, particle size, tablet integrity, food effects, and gastrointestinal exposure can differ materially. FDA labeling commonly instructs patients to take tablets with meals and water and to swallow them whole.[1-4]

What excipients are used in potassium chloride extended-release formulations?

The principal excipient categories are release-controlling polymers, binders, lubricants, glidants, coating systems, diluents, and capsule materials.

Release-controlling excipients

The most commercially relevant release systems include:

• Ethylcellulose coatings or matrices
• Hypromellose, also known as hydroxypropyl methylcellulose
• Cellulosic binders and film-forming polymers
• Microencapsulation polymers
• Hydrophobic waxes or lipid-based barriers
• Polymer-lipid combinations

Ethylcellulose is attractive because it provides water-insoluble diffusion control and can be applied to potassium chloride particles or incorporated into a matrix. Hypromellose can form a hydrated gel layer that slows dissolution. A combination of hydrophobic and hydrophilic polymers can create a more robust release profile across gastric and intestinal conditions.

Core excipients

Typical core excipients may include:

• Microcrystalline cellulose
• Povidone
• Crospovidone, where limited disintegration is desired
• Silicon dioxide
• Magnesium stearate
• Talc
• Starches or modified starches
• Calcium-based or cellulose-based diluents

The formulation objective differs from an immediate-release tablet. The product must maintain mechanical integrity while preventing rapid local dissolution of a concentrated potassium salt.

Capsule and multiparticulate excipients

Microencapsulated potassium chloride products can use coated crystals or pellets filled into hard gelatin or hypromellose capsules. Multiparticulate systems provide several commercial advantages:

1. Reduced dependence on one large monolithic tablet.
2. More consistent gastrointestinal dispersion.
3. Potentially improved swallowing characteristics.
4. Greater flexibility for sprinkle or suspension administration, subject to labeling and bioequivalence requirements.

The critical formulation variable is coating integrity. Damaged or incompletely coated particles can release potassium too quickly and create unacceptable local exposure.

Which excipient strategy is strongest for a new potassium chloride ER product?

A layered multiparticulate strategy is generally more defensible commercially than a basic compressed matrix tablet.

Option 1: Hydrophilic matrix tablet

A hydrophilic matrix using hypromellose is relatively simple to manufacture and can support multiple strengths through proportional scaling. Its disadvantages are dose dumping risk under mechanical stress, sensitivity to compression conditions, and potential variability in release caused by tablet dimensions and excipient grade.

This approach is most suitable for a low-cost generic or authorized-generic strategy where the reference product has a comparable matrix architecture.

Option 2: Hydrophobic matrix tablet

Ethylcellulose or wax-based matrices can slow water penetration and reduce rapid release. The system can be more robust against pH variation, but it may require careful control of granulation, compression force, and particle distribution.

The principal development risk is achieving a release profile that is neither too slow nor too variable. Excessive retardation can reduce potassium availability, while insufficient control can increase gastrointestinal exposure.

Option 3: Coated crystals or microencapsulated particles

A multiparticulate system can distribute potassium chloride throughout the gastrointestinal tract. Coated crystals also allow release control to be separated from tablet hardness and disintegration.

This approach is attractive for:

• Sprinkle capsules
• Smaller-unit-dose products
• Pediatric or geriatric administration
• Products intended to reduce tablet size
• Line extensions with different strengths

It requires more complex coating equipment and stronger in-process controls. Coating thickness, weight gain, particle friability, agglomeration, and dissolution after storage are central critical quality attributes.

Option 4: Osmotic or specialty delivery systems

Osmotic systems can provide controlled release but are difficult to justify economically for a commodity electrolyte. The approach may be commercially relevant only when paired with a clear clinical or administration advantage, such as reduced dosing frequency or improved tolerability.

What critical quality attributes control potassium chloride ER performance?

The most important quality attributes are dissolution profile, dose uniformity, tablet or capsule integrity, mechanical strength, particle-size distribution, and stability.

A robust development program should evaluate:

Attribute	Commercial relevance
Potassium assay	Confirms dose accuracy
Content uniformity	Controls variability between units
Dissolution at multiple pH values	Demonstrates release consistency
Release under fed and fasted conditions	Addresses administration variability
Tablet hardness and friability	Protects against breakage and dose dumping
Coating weight gain	Controls multiparticulate release
Particle-size distribution	Affects dissolution and GI dispersion
Moisture uptake	Can alter coating, hardness, and dissolution
Packaging integrity	Protects high-dose solid units from humidity
Extractables and leachables	Relevant for polymeric packaging and coatings

Potassium chloride is highly soluble. This increases the need for a reliable barrier system because exposed drug can dissolve rapidly. Dissolution testing should include early time points capable of detecting an initial burst, not only later cumulative release.

What FDA regulatory pathway applies to potassium chloride extended-release?

Most new generic potassium chloride extended-release products would proceed through an abbreviated new drug application under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference-listed drug.[5]

The development burden is higher than for a conventional immediate-release tablet because modified-release products require evidence that the release profile and systemic exposure are comparable. A sponsor may need:

• Fasting pharmacokinetic studies
• Fed pharmacokinetic studies
• Multiple-dose studies
• Comparative dissolution profiles
• Strength-specific bridging
• In vitro release characterization
• Food-effect analysis
• Assessment of dose dumping or altered release after mechanical stress

The product must also comply with potassium chloride labeling requirements. FDA labeling emphasizes that extended-release potassium chloride tablets should not be crushed, chewed, or sucked because rapid release can increase gastrointestinal risk.[1-4]

A 505(b)(2) application may be relevant for a new dosage form, new administration route, or clinically differentiated formulation that cannot rely fully on an ANDA pathway. That route could support a liquid-filled capsule, sprinkle product, or new delivery system, but it requires a stronger commercial rationale and potentially additional clinical evidence.

What patents protect potassium chloride extended-release products?

The core potassium chloride molecule is an old, unpatented electrolyte. The principal historical IP value has been in dosage forms, microencapsulation, controlled-release matrices, manufacturing processes, and specific combinations of excipients.

For currently marketed products, the practical patent position is generally weak compared with newer prescription medicines. The main barriers are regulatory and technical rather than long-lived compound patents.

Relevant IP categories include:

IP category	Potential scope	Current commercial importance
Microencapsulated potassium chloride	Coated crystals, pellet structures, release control	Moderate for differentiated capsules
Matrix tablets	Polymer composition and manufacturing process	Low to moderate
Multilayer tablets	Spatial distribution of potassium and excipients	Moderate if performance is distinctive
Sprinkle formulations	Capsule contents and administration method	Moderate
Packaging and moisture control	Container-closure system	Low patent value, high operational value
Manufacturing process	Granulation, coating, compression, and control steps	Moderate where difficult to replicate
Method-of-use claims	Treatment of hypokalemia or prevention of potassium loss	Generally weak because the therapeutic use is established

Patent analysis should be conducted against the current FDA Orange Book listings for each reference-listed drug, because listings can differ by product, strength, formulation, and sponsor.[6] Older potassium chloride products have historically faced generic competition, and many foundational formulation patents have expired.

When does potassium chloride extended-release lose exclusivity?

Potassium chloride extended-release products generally have no meaningful remaining new-drug exclusivity based on the active ingredient. Regulatory exclusivity is therefore determined mainly by the applicable reference product and any surviving formulation or method-of-use listings.

A generic applicant may challenge listed patents through a Paragraph IV certification under the Hatch-Waxman framework. If the brand sponsor files a timely infringement action, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court decisions.[7]

For a mature product, the more likely commercial scenario is that an ANDA applicant proceeds after evaluating:

• Orange Book-listed patents
• Patent expiration dates
• Pediatric exclusivity, if any
• 30-month stay exposure
• Paragraph IV litigation risk
• Reference-product availability
• Product-specific bioequivalence requirements

There is no biosimilar pathway for potassium chloride. It is a small-molecule electrolyte, so competitive entry occurs through ANDAs, 505(b)(2) applications, private-label supply, or over-the-counter-adjacent channels where permitted by the product’s regulatory status.

Which companies are challenging potassium chloride extended-release products?

The market has historically included branded manufacturers, generic pharmaceutical companies, and contract manufacturers. Generic competition is typically fragmented because the formulation can be manufactured by multiple suppliers with established oral solid-dose capabilities.

Competitive participants may include:

• The sponsor of the reference-listed brand
• Large generic companies with broad ANDA portfolios
• Specialty generic manufacturers focused on modified-release products
• Contract development and manufacturing organizations
• Private-label distributors and institutional suppliers

The primary competitive issue is usually not Paragraph IV litigation. It is reliable supply at acceptable cost. Potassium chloride shortages or manufacturing interruptions can shift hospital and pharmacy purchasing rapidly because the product is clinically necessary and substitution options may be limited by dosage form.

What commercial opportunities exist in potassium chloride extended-release?

The strongest opportunities are product improvements that address administration and tolerability rather than small changes in release kinetics.

Smaller tablets and flexible dosing

High potassium doses create large tablets. A company that can reduce tablet size without increasing burst release may gain access to patients who have difficulty swallowing conventional products.

Multiple-unit dosing can also support more flexible titration. For example, 10 mEq and 20 mEq presentations may be supplemented by 8 mEq or 15 mEq strengths where the reference product and market support those configurations.

Sprinkleable capsules

A capsule containing coated potassium chloride particles can target patients who cannot swallow tablets. The commercial value depends on whether the particles can be administered with soft food without being crushed or chewed and whether the labeling supports that use.

The product must preserve release performance after opening the capsule. This creates a formulation and regulatory distinction from a conventional capsule.

Improved gastrointestinal tolerability

Potassium chloride can cause nausea, abdominal discomfort, vomiting, diarrhea, ulceration, or gastrointestinal bleeding. A product that reduces local concentration peaks may have clinical and commercial value, but tolerability claims require appropriate evidence.

Potential approaches include:

• Better particle dispersion
• Lower burst release
• More uniform coating
• Reduced tablet size
• Controlled gastric residence
• Administration instructions aligned with food intake

A tolerability claim based only on excipient selection is unlikely to create durable market protection without comparative clinical evidence.

Hospital and institutional packaging

Unit-dose blister packs, moisture-resistant bottles, and barcode-ready packaging can improve institutional purchasing. Packaging is not normally a high-value patent moat, but it can support formulary adoption and reduce medication-administration errors.

Supply-chain differentiation

Because the API is inexpensive, a reliable supply chain can matter more than a small reduction in manufacturing cost. Commercial advantages may come from:

• Dual-source API qualification
• Domestic or regional manufacturing
• Higher process capability for coating
• Stable inventory of high-demand strengths
• Contract packaging flexibility
• Short lead times for hospital tenders

How strong is the patent estate for potassium chloride extended-release?

The patent estate is weak for commodity generic entry and stronger for technically differentiated delivery systems.

Factor	Assessment
API patent protection	None of practical significance
New chemical entity exclusivity	Not applicable
Broad formulation patents	Mostly historical or narrow
Method-of-use protection	Limited practical value
Manufacturing know-how	Moderate
Multiparticulate coating know-how	Moderate to strong
Regulatory complexity	Moderate
Bioequivalence risk	Moderate to high for modified-release products
Supply-chain barrier	Moderate
Brand loyalty	Low to moderate
Price competition	High

The strongest defensible position is likely a combination of formulation know-how, product-specific regulatory data, manufacturing controls, and a differentiated administration profile. A single broad excipient patent is unlikely to support durable market power.

What patent litigation and settlement risks affect the product?

Patent litigation risk is generally lower than for recently approved small-molecule medicines because potassium chloride extended-release products are mature and widely genericized. Risk can still arise when a sponsor introduces:

• A new sprinkle formulation
• A novel microencapsulation process
• A proprietary multilayer tablet
• A controlled-release profile with a new clinical claim
• A new combination product
• A specialty dosage form supported by a 505(b)(2) application

Settlement agreements in such cases could affect the timing of generic or authorized-generic entry. Standard commercial terms may include licensed entry dates, supply arrangements, or restrictions tied to specific strengths or dosage forms. The financial impact is usually product-specific and depends on whether the differentiated product has substantial market share.

How does potassium chloride extended-release compare with other electrolyte products?

Product type	Main advantage	Main disadvantage	Commercial opportunity
Potassium chloride ER tablet	Low cost and established use	Large tablets; GI risk	Generic supply and smaller tablets
Microencapsulated capsule	Particle-based release; potential administration flexibility	More complex manufacture	Sprinkle and dysphagia markets
Potassium chloride liquid	Flexible dosing; suitable for swallowing impairment	Taste, dosing errors, stability	Pediatric, geriatric, and institutional use
Potassium citrate ER	Different therapeutic and urinary applications	Not a direct substitute for all hypokalemia cases	Niche indication expansion
Oral rehydration products	Broader electrolyte replacement	Lower potassium concentration	Consumer and outpatient channels
Intravenous potassium chloride	Rapid controlled administration in hospital	Administration risk and monitoring burden	Acute-care use only

Potassium chloride ER competes primarily on dose delivery, tolerability, and cost. It does not compete directly with potassium citrate in every indication because the anion changes the clinical and metabolic profile.

What generic launch scenarios exist for potassium chloride ER?

A new entrant could pursue four principal scenarios:

1. Low-cost conventional ANDA launch. This approach targets pharmacy substitution and institutional contracts. It requires efficient manufacturing but offers limited differentiation.

2. Strength expansion. A sponsor may launch an underrepresented strength or package configuration, subject to regulatory and market demand. The opportunity is larger where prescribers need incremental dosing.

3. Multiparticulate or sprinkle product. This strategy targets swallowing-impaired patients and specialty pharmacies. It requires stronger formulation development and potentially more complex regulatory support.

4. 505(b)(2) differentiated product. A sponsor could pursue a novel delivery system or administration method. The opportunity is higher value but carries greater development, clinical, and patent costs.

The preferred strategy depends on whether the target buyer is a retail pharmacy, hospital system, long-term-care provider, specialty distributor, or direct-to-consumer channel.

What are the geographic opportunities for potassium chloride extended-release?

The United States offers the clearest ANDA framework and a large generic pharmacy market. Europe, Canada, Japan, and emerging markets have separate requirements for modified-release bioequivalence, labeling, and excipient acceptability.

Geographic expansion should account for:

• Different potassium chloride strength conventions
• Milliequivalent versus milligram labeling
• Country-specific reference products
• Food-effect requirements
• Availability of excipients
• Pediatric administration standards
• Packaging and serialization rules
• Local GMP expectations
• Hospital tender structures

A global formulation may require regional excipient changes because excipient monographs, permitted grades, and regulatory precedents differ.

Key Takeaways

• Potassium chloride extended-release is a mature, highly price-sensitive market.
• The API has no meaningful modern composition-of-matter exclusivity.
• Commercial protection depends on formulation performance, manufacturing controls, regulatory data, and supply reliability.
• Ethylcellulose, hypromellose, microcrystalline cellulose, povidone, magnesium stearate, silicon dioxide, and capsule or coating materials are central excipient categories.
• Multiparticulate and sprinkleable products offer the clearest differentiation opportunity.
• Smaller tablets, flexible strengths, improved GI tolerability, and institutional packaging are commercially relevant extensions.
• ANDA entry is the principal route for conventional generic products.
• 505(b)(2) may support a genuinely differentiated dosage form but requires greater investment.
• Paragraph IV and patent litigation risk is generally lower than for newer prescription drugs, although novel delivery systems can create new disputes.
• There is no biosimilar pathway because potassium chloride is a small-molecule electrolyte.
• Manufacturing know-how and supply continuity are more important barriers than broad patent protection.

FAQs About Potassium Chloride Extended-Release Commercialization

Can potassium chloride extended-release tablets be reformulated with different excipients?

Yes, but the sponsor must demonstrate that the formulation remains pharmaceutically equivalent and bioequivalent to the reference product. A change in polymer type, grade, coating level, or tablet structure can materially alter dissolution and systemic exposure.

Is a smaller potassium chloride ER tablet commercially viable?

Yes. Smaller tablets can address swallowing difficulty and improve adherence, but dose concentration and release control become more challenging. The product must preserve dose uniformity and avoid rapid potassium release.

Does potassium chloride extended-release require a controlled-release coating?

Not necessarily. A matrix system can control release, but coated crystals, pellets, multilayer tablets, and other systems may provide better control or administration flexibility.

Can a potassium chloride sprinkle capsule be sold as a generic?

Potentially. The sponsor must establish equivalence to the appropriate reference product and demonstrate that opening the capsule or administering the contents with food does not compromise release performance if that use is claimed.

What is the main investment risk in a potassium chloride ER development program?

The principal risk is failure to match the reference product’s release and exposure profile while maintaining acceptable mechanical strength, stability, and gastrointestinal tolerability. The API cost is low, but modified-release development and bioequivalence testing can be technically demanding.

References

1. U.S. Food and Drug Administration. (2023). Klor-Con M potassium chloride extended-release tablets: Prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2023). Klor-Con potassium chloride extended-release tablets: Prescribing information. FDA/DailyMed.

3. U.S. Food and Drug Administration. (2023). Micro-K potassium chloride extended-release capsules: Prescribing information. FDA/DailyMed.

4. U.S. Food and Drug Administration. (2023). Potassium chloride extended-release tablets: Prescribing information. FDA/DailyMed.

5. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products: General considerations. FDA.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

7. U.S. Government Publishing Office. (2024). 21 U.S.C. § 355: New drugs. United States Code.